LLY

922.4

-0.08%↓

UNH

589.22

-0.85%↓

NVO

137.37

+0.29%↑

JNJ

166.55

+0.63%↑

ABBV

195.28

+0.62%↑

LLY

922.4

-0.08%↓

UNH

589.22

-0.85%↓

NVO

137.37

+0.29%↑

JNJ

166.55

+0.63%↑

ABBV

195.28

+0.62%↑

LLY

922.4

-0.08%↓

UNH

589.22

-0.85%↓

NVO

137.37

+0.29%↑

JNJ

166.55

+0.63%↑

ABBV

195.28

+0.62%↑

LLY

922.4

-0.08%↓

UNH

589.22

-0.85%↓

NVO

137.37

+0.29%↑

JNJ

166.55

+0.63%↑

ABBV

195.28

+0.62%↑

LLY

922.4

-0.08%↓

UNH

589.22

-0.85%↓

NVO

137.37

+0.29%↑

JNJ

166.55

+0.63%↑

ABBV

195.28

+0.62%↑

Home・Aktien・Nektar Therapeutics

Nektar Therapeutics

Geschlossen

1.3 4

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

1.3

Max

1.33

Schlüsselkennzahlen
By Trading Economics
Einkommen	-46M
Verkäufe	-259K 24M
EPS	-0.22
Gewinnspanne	-189.848
Angestellte	137
EBITDA	-32M

Empfehlungen
By TipRanks
Empfehlungen	Buy
12-Monats-Prognose	+52.67 upside

Dividenden
By Dow Jones
Nächstes Ergebnis	5. Nov. 2024

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	-20M 230M
Vorheriger Eröffnungskurs	-2.7
Vorheriger Schlusskurs	1.3

Technischer Score

By Trading Central

Vertrauen

Weak Bullish Evidence

1.24 / 1.31 Unterstützung & Widerstand

Nektar Therapeutics Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

14. Sept. 2024, 01:45 UTC

Ergebnisse

Preview -- Barron's

13. Sept. 2024, 20:03 UTC

Top News

Walgreens to Pay $106.8 Million Over Alleged Fraudulent Healthcare Billings

15. Sept. 2024, 23:47 UTC

Market Talk

Gold Edges Higher Amid Mild Dollar Weakness -- Market Talk

15. Sept. 2024, 23:03 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

15. Sept. 2024, 23:03 UTC

Market Talk

Australian Bond Traders Watchful as Fed Easing Nears -- Market Talk

15. Sept. 2024, 16:52 UTC

Top News

Boeing Machinist Strike Adds Cash Crunch to New CEO's Rescue Mission -- WSJ

15. Sept. 2024, 09:30 UTC

Top News

Interest Rates Are Too High. The Fed Should Cut by a Half Point. -- WSJ

15. Sept. 2024, 07:00 UTC

Top News

World's Biggest Hedge Fund Sells Apple, Eli Lilly Stock, and Buys Microsoft, Moderna -- Barrons.com

14. Sept. 2024, 14:09 UTC

Top News

Disney, DirecTV Reach Deal, Ending Blackout of ABC, ESPN -- Update 1 -- WSJ

14. Sept. 2024, 13:25 UTC

Top News

Disney, DirecTV Reach Deal, Ending Blackout of ABC, ESPN -- WSJ

14. Sept. 2024, 09:30 UTC

Top News

Why a Fed Rate Cut Won't Solve the Housing Wealth Gap -- WSJ

14. Sept. 2024, 09:30 UTC

Top News

Americans Are Falling Behind on Their Bills. Wall Street Is Alarmed. -- WSJ

14. Sept. 2024, 03:00 UTC

Top News

What Scared Ford's CEO in China -- WSJ

14. Sept. 2024, 03:00 UTC

Top News

What Scared Ford's CEO in China -- WSJ -2-

14. Sept. 2024, 00:01 UTC

Top News

Why 96% of Boeing's Machinists Voted to Go on Strike -- Update

13. Sept. 2024, 21:14 UTC

Top News

Why 96% of Boeing's Machinists Voted to Go on Strike -- WSJ

13. Sept. 2024, 21:06 UTC

Top News

Starliner Astronauts Say NASA Ran Short of Time to Test Boeing Craft -- WSJ

13. Sept. 2024, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

13. Sept. 2024, 20:47 UTC

Market Talk

Saudi Arabia Credit Outlook Raised to Positive on Economic Investments -- Market Talk

13. Sept. 2024, 20:44 UTC

Akquisitionen, Fusionen, Übernahmen

Schlumberger Stock Was Once as Hot as Nvidia. Why It's a Buy. -- Barrons.com

13. Sept. 2024, 20:41 UTC

Top News

Berkshire Hathaway's Stock Is So Rich Even Berkshire Is Buying Less of It -- Update

13. Sept. 2024, 20:31 UTC

Ergebnisse

These Stocks Moved the Most Today: Adobe, Boeing, Trump Media, Oracle, Uber, RH, Moderna, Etsy, and More -- Barrons.com

13. Sept. 2024, 20:13 UTC

Akquisitionen, Fusionen, Übernahmen

BlackRock: Expects to Close Previously Announced Acquisition of Global Infrastructure Partners on Oct 1 >BLK

13. Sept. 2024, 20:10 UTC

Akquisitionen, Fusionen, Übernahmen

BlackRock Announces Expected Closing Date For Acquisition Of Global Infrastructure Partners >BLK

13. Sept. 2024, 20:02 UTC

Akquisitionen, Fusionen, Übernahmen

CGI Completes Acquisition Of Aeyon, Expands Capabilities For National Security And Civilian Agency Missions >GIB

13. Sept. 2024, 20:02 UTC

Akquisitionen, Fusionen, Übernahmen

CGI Completes Acquisition Of Aeyon, Expands Capabilities For National Security And Civilian Agency Missions >GIB

13. Sept. 2024, 19:44 UTC

Market Talk

Treasury Yields Fall as Odds of 50bp Fed Cut Rise -- Market Talk

13. Sept. 2024, 19:20 UTC

Market Talk

Crude-Oil Futures End Week With Small Gains -- Market Talk

13. Sept. 2024, 19:09 UTC

Market Talk

U.S. Natural-Gas Futures Post Weekly Gain -- Market Talk

13. Sept. 2024, 18:01 UTC

Market Talk

Gold Analysts Call For New Leg Of Rally -- Market Talk

Peer-Vergleich

Kursveränderung

Nektar Therapeutics Prognose

Kursziel

By TipRanks

52.67% Vorteil

12-Monats-Prognose

Durchschnitt 2 USD 52.67%

Hoch 2 USD

Tief 2 USD

Basierend auf 2 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Nektar Therapeutics – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

2 ratings

Buy

Halten

Sell

Basierend auf 2 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Nektar Therapeutics – Dist abgegeben haben.

Technischer Score

By Trading Central

1.24 / 1.31Unterstützung & Widerstand

Recent bullish events outweigh bearish events.

There is one bullish event.

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Nektar Therapeutics

Nektar Therapeutics is a biopharmaceutical company. The Company discovers and develops medicines in areas of unmet medical need. Its research and development pipeline of new investigational drugs includes treatments for cancer and autoimmune disease. It has research and development (R&D) pipeline of medicines in oncology, immunology, and virology as well as a portfolio of approved partnered medicines. It leverages its chemistry platform to discover and design new drug candidates. These drug candidates utilize its polymer conjugate technology platforms, which are designed to enable the development of new molecular entities. Its R&D pipeline includes Bempegaldesleukin (NKTR-214), NKTR-358, NKTR-262 and NKTR-255. It develops medicines designed to modulate the activity of key immune cells, such as cytotoxic T cells and Natural Killer (NK) cells, to increase their numbers and improve their function to recognize and attack cancer cells directly or indirectly.